[ sulge aken ]
| Elulookirjeldus (CV) | ||
| 1. | Eesnimi | Margus |
| 2. | Perekonnanimi | Viigimaa |
| 3. | Töökoht | Eesti Kardioloogia Instituut Tallinna Tehnikaülikool (osalise koormusega) |
| 4. | Ametikoht | Preventiivse kardioloogia osakonna juhataja Kardiovaskulaarse meditsiini professor |
| 5. | Sünniaeg | 24.04.1958 (päev.kuu.aasta) |
| 6. | Haridus | Tartu Ülikool 1982 - arstidiplom (kiitusega), Kaunase Meditsiiniakadeemia 1989 - meditsiinikandidaat, Tartu Ülikool 1994 - meditsiinidoktor, postdok. stažeerimine Kyoto Ülikoolis (Japan)1990-1991 |
| 7. | Teenistuskäik | 1982-1989 TÜ ÜMPI kliinilise füsioloogia labori n.-teadur; 1989-1991 TÜ ÜMPI kliinilise füsioloogia labori v.-teadur, al. 1991 labori juhataja; aastatel 1994-1996 TÜ kardioloogia kliiniku v.-teadur; 1996.-2004. a TÜ Kardioloogia kliiniku dotsent; al. 2005. a. PERH Kardioloogiakeskuse juhataja; al. 2005 Eesti Kardioloogia Instituudi osakonnajuhataja, TTÜ professor. |
| 8. | Teaduskraad | Meditsiinikandidaat Meditsiinidoktor |
| 9. | Teaduskraadi välja andnud asutus, aasta |
Kaunase Meditsiiniakadeemia 1989 Tartu Ülikool 1994 |
| 10. | Tunnustused | Rootsi Hüpertensiooni Ühingu auliige (2000) |
| 11. | Teadusorganisatsiooniline ja –administratiivne tegevus |
Ajakirja "Baltic Atherosclerosis Journal" peatoimetaja Ajakirja "Seminars in Cardiology" asepeatoimetaja Eesti Hüpertensiooni Ühingu ekspresident Ajakirja "Vererõhk" toimetuskolleegiumi liige WHO CINDI programmi Eesti direktor Eesti Hüpertensioonijuhiste koostetoimkonna esimees Eesti Lipiidijuhiste koostetoimkonna esimees Eesti Kardioloogide Seltsi ekspresident Balti Ateroskleroosi Ühingu valitud president Euroopa Hüpertensiooni Ühingu juhatuse liige Euroopa Kardioloogide Seltsi Crentials committee liige Konverentside korraldamine: 1995. a. Eesti I Südametervise konverentsi pôhiorganisaator (Tallinn) 1995. a. Rahvusvahelise Hüpertensiooni Ühingu Eesti loengusarja pôhiorganisaator . 1996. a. Eesti II Südametervise konverentsi pôhiorganisaator (Tallinn) 1996. a. Eesti Kardioloogide debattide peakorraldaja (Tallinn) 1997. a. Eesti III Südametervise konverentsi pôhiorganisaator (Tallinn) 1997. a. Balti Riikide Kardioloogide konverentsi (Palanga)Eestipoolne pôhiorganisaator 1997. a. Eesti ja Soome Hüpertersiooni Ühingute ühiskonverentsi (Tallinn) pôhiorganisaator 1997.a. Euroopa Kliiniliste Uuringute Ühingu 31. aastakonverentsi (Kielis, Saksamaa) trombotsüütide aktivatsiooni sektsiooni üks organisaatoreid, istungi juhataja. 1998.a. I Balti riikide ja Põhjamaade Hüpertensiooni Konverentsi peakorraldaja (Tallinn) 1998. a. I Balti Lipiidikongressi peakorraldaja (Tallinn) 2000.a. X Euroopa Hüpertensiooni konverentsi Tallinna satelliitsümpoosiumi peakorraldaja. 2001.a II Balti riikide ja Põhjamaade Hüpertensiooni Konverentsi korraldaja (Riia) 2001. a. II Balti Ateroskleroosi Kongressi korraldaja (Vilnius) 2003. a. I Balti Kardioloogide Kongressi peakorraldaja (Pärnu) 2004. a. III Balti Ateroskleroosi Kongressi korraldaja (Riia) 2005 .a III Balti riikide ja Põhjamaade Hüpertensiooni Konverentsi korraldaja (Vilnius) |
| 12. | Juhendamisel kaitstud väitekirjad |
Simon Janes, MSc, 1999, juh. Margus Viigimaa, Stan Heptinstall. "Studies on platelet responsiveness to ADP in coronary patients in Estonia". Nottinghami Ülikool |
| 13. | Teadustöö põhisuunad | Vere hüübimishäirete diagnostika ja ravi kardioloogilistel haigetel, arteriaalne hüpertensioon, hüperlipideemiad ja preventiivkardioloogia. 1. Primaarse hemostaasi patoloogia ja antiagregantravi müokardi infarkti haigetel. 2. Südame isheemiatõve haigete antikoagulantravi. 3. Esmane hemostaas hüperlipideemiate korral ja selle môjustatavus lipiidelangetava raviga. 4. Südame-veresoonkona haiguste riskitegurite võrdlus Eesti ja Rootsi elanikel. 5. Arteriaalse hüpertensiooni patsientide kodujälgimie telemeditsiiniliste aparaatide väljatöötamine ja kliinilised uuringud. |
| 14. | Jooksvad grandid | Puuduvad |
| 15. | Teaduspublikatsioonid |
Port, K., Palm, K., Viigimaa M. (2005) Gaily usage and efficiency of remote home monitoring in hypertensive patients over a one-year period. Journal of Teklemedicine and Telecare, 11 Suppl.1, 34-36. Port, K., Palm, K., & Viigimaa, M. (2003). Self-Reported Compliance of Patients Receiving Antihypertensive Treatment: Use of a Telemonitoring Home Care System. Journal of Telemedicine and Telecare, 9, S65-S66. Viigimaa M, Kask A, Tiganik V et al. Cardiovascular risk factors in 55-year-old women and men in Tartu (Estonia) and Stockholm (Sweden). Atherosclerosis Supplements 4 (2):110-110 Sep 2003. Johansson, J., Viigimaa, M., Jensen-Urstad, M., Krakau, I., & Hansson, L. O. (2002). Risk Factors for Coronary Heart Disease in 55-and 35-Year-Old Men and Women in Sweden and Estonia. Journal of Internal Medicine, 252(6), 551-560. Muda P, Ristimäe T, Viigimaa M. Arterial hypertension among middle-aged Estonians - Prevalence and risk factors. Journal of Hypertension 20: P345 Suppl. 4 jun 2002 Allikmets K, Starkopf A, Svensson S et al. Ambulatory blood pressure monitoring in a population of an Estonian island: initial results from the SELECT project. European Heart Journal 22: 10-103. Suppl. S Sep 2001 Unden, A. L., Elofsson, S., Viigimaa, M., Johansson, J., & Knox, S. (2001). A Psychosocial Comparison of 35- and 55-Year-Old Men and Women in Sweden and Estonia: the Swestonia Cardiovascular Risk Factor Study. International Journal of Behavioral Medicine, 8(2), 149-162. Allikmets K., Ristimäe T., Viigimaa M. Electrocardiographic detection of left ventricular hypertrophy in severe essential hypertension: correlations between different models. Journal of Hypertension 18: S28-S28 Suppl. Jun 2000 Svensson S, Allikmets K, Petreson J,.... Viigimaa M... The Swedeshy-Estonian long-term evaluation of cardiovascular risk trends (SELECT) project initial resultsw. Journal of Hypertension 18: S179-S179 Duppl.2 Jun 2000 Viigimaa, M., Allikmets, K., Parik, T., Skards, J., Franken, A., & Hass, G. (2000). Tasosartan and Hydroclorothiazide as Combination Therapy in the Treatment of Severe Essential Hypertension: Comparison With Enalapril. Cardiovascular Drugs and Therapy, 14(4), 447-449. Allikmets, K., Parik, T., & Viigimaa, M. (1999). The Renin-Angiotensin System in Essential Hypertension: Associations With Cardiovascular Risk. Blood Pressure, 8(2), 70-78. Viigimaa M. Baltic Atherosclerosis Journal [2](1999) Clinical Chemistry and Laboratory Medicine, 37 (8),841-841. Viigimaa M, Kask A, Tiganik V et al. Comparision of the lipid profile and eating habits of 35-year and 55-year old inhabitants of the city Tartu (estonia). Atherosckerosis 144: 176-176 Suppl. 1 May 1999 Viigimaa M, Kask A, Tigank V et al. A comparison of blood pressure levels, lipid profiles and smoking habits between 35-year olds in Tartu (Estonia) and Stockholm (Sweden). Hypertension 33 (5): 1320-1320 May 1999 Täpselt sama pealkirjaga ka Hypertension 33 (4): 275 Apr 1999 (?) Viigimaa M, Valkman R. Lipid-lowering and antiaggregatory effacasy of atrovastatin in coronary heart disease patients with combined hyperlipuidamia. Atherosckerosis 144: 24-24 Suppl.1 May 1999 Ojamaa M, Viigimaa M, Slim K et al. Ambulatory blood pressure monitoring in young males with borderline hypertension. Journal of Hypertension 16:L P27117 Suppl. 2 Jun 1998 Parik T, Allikmets K, Zilmer K... Voogomaa M et al, Associations between oxydative stress, Von Willebrand factor and plasminogen activator Inhibitor 1 in essential hypertension. Journal of Hypertension 16: P27041 Suppl.2 Jun 1998 Viigimaa ,M., Välkman, R., Kask, A., Jõudu, T. (1998) Effect of ciprofibrate on platelet aggregation in patients with combined hyperlipidemia. Platelets, 9 (3-4), 265-267. Viigimaa, M., Tsikas, Frölich, J.C. (1996) Platelet aggregation, sensitivity to prostaglandin E1 and tromboxane A2 release in recombinant hirudin- and heparin-anticoagulated blood. Blood Coagulation and Fibrinolysis, 7 (2), 259-261. Viigimaa, M., Joudu, T., Keis, U., Saareoja, Y., Teesalu, R. (1995) Platelet aggregation, tromboxane A2, Prostacycline generation and platelet sensitivity to prostacyclin during the first month after myocardial infarction. Platelets 6 (6), 402-407. Viigimaa M, Saareoja Y. Prospective study on activates protein-C resistance in patients wuth acute myocardial-infarction. Thrombosis and Haemastasis 73 (6): 1374-1374 Jun 1995 Viigimaa M, Ohnogi H, Hattori R et al. Antithrombotic effect and reperfusion by low-molecular-weight heparin in a canine model of coronary-artery thrombosis. Japanese Circulation Journal - English Edistion 57 (6): 553-557. 1993 Lopp M, Kobzar G, Bergamnann M... Viigimaa M,,, Synthesis and anti aggregative activity of novel omega-achiral carba-analogs of prostacyclin. European Journal of Medicinal Chemistry 27 (2): 155-159. Mar 1992 |
viimati muudetud: 16.10.2005
| Curriculum Vitae (CV) | ||
| 1. | First Name | Margus |
| 2. | Surname | Viigimaa |
| 3. | Institution | Estonian Institute of Cardiology Tallinn University of Technology (part time) |
| 4. | Position | Head of the Department of Preventive cardiology Professor of Cardiovascular Medicine |
| 5. | Date of birth | 24.04.1958 (day.month.year) |
| 6. | Education | University of Tartu 1982 - MD, Kaunase Medical Academy (Lithuania) 1989 - candidate of medical sciences, University of Tartu 1994 - PhD (cardiology), Postdoctoral research in the Kyoto University (Japan) 1990-1991 |
| 7. | Research and professional experience |
1982-1991 Researcher of the Laboratory of Clinical Physiology, University of Tartu; 1991-1996 Head of the Laboratory of Clinical Physiology, University of Tartu; 1996-2004 Ass. Prof. of the Clinic of Cardiology, University of Tartu; since 2005 Estonian Institute of Cardiology, Head of the Department, Tallinn University of Technology, Professor. |
| 8. | Academic degree | Candidate of Medical Sciences PhD (cardiology) |
| 9. | Dates and sites of earning the degrees |
Kaunas Medical Academy (Lithuania) 1989 University of Tartu 1994(cardiology). |
| 10. | Honours/awards | Honorary Member of the Swedish Society of Hypertension (2000) |
| 11. | Research-administrative experience |
Editor of the "Baltic Atherosclerosis Journal" Editor of the joint Baltic journal “Seminars in Cardiology” Member of the Editorial Board of the Journal "Vererõhk" (Blood Pressure) Chairman of the task force of the Estonian Hypertension Guidelines Chairman of the task force of the Estonian Lipid Guidelines Past-President of the Estonian Society of Cardiology Past-President and founder of the Baltic Society of Atherosclerosis Founder and first President of the Estonian Society of Hypertension (1995-2000) Member of the Board of the Estonian Society of Hypertension (since 2000) Board member of the European Society of Hypertension Member of the Credentials Committee, European Society of Cardiology Estonian WHO CINDI Programme Director Meeting organisation: 1995 Estonian I Heart Health Conference in Tallinn (main organiser) 1995 Conference of the International Society of Hypertension (main organiser) 1996 Estonian II Heart Health Conference in Tallinn (main organiser) 1996 Estonian Cardiology Conference (main organiser) 1997 Estonian III Heart Health Conference in Tallinn (main organiser) 1997 Baltic Cardiology Conference in Palanga (main organiser) 1997 Estonian-Finnish Hypertension meeting in Tallinn (main organiser) 1997 31. Conference of the European Society for Clinical Research in Kiel (co-organiser) 1998 I Baltic-Nordic Meeting on Hypertension in Tallinn (main organiser) 1998 I Baltic Lipid Conference in Tallinn (main organiser) 2000 X European Meeting on Hypertension, Tallinn Satellite Conference (main organiser) 2001 II Baltic-Nordic Meeting on Hypertension in Riga (co-organiser) 2001 II Baltic Atherosclerosis Congress in Vilnius (co-organiser) 2003 I Baltic Cardiology Conference in Pärnu (main organiser) 2004 III Baltic Atherosclerosis Congress in Riga (co-organiser) 2005 III Baltic-Nordic Meeting on Hypertension in Vilnius (co-organiser) |
| 12. | Supervised dissertations |
Simon Janes, MSc, 1999, superv. Margus Viigimaa, Stan Heptinstall. "Studies on platelet responsiveness to ADP in coronary patients in Estonia". Nottinghami Ülikool |
| 13. | Current research program | Blood coagulation disorders and their treatment in patients with heart diseases, arterial hypertension, dyslipidemia, cardiovascular prevention. 1. Primary hemostasis and antiaggregatory therapy in patients with myocardial infarction. 2. Anticoagulation treatment in patients with coronary heart disease. 3. Primary haemostasis disorders in dyslipidemic patients and effects of lipid-lowering therapy. 4. Comparison of cardiovascular risk factors in Swedish and Estonian inhabitants. 5. Home monitoring of patients with arterial hypertension using telemetric devices. |
| 14. | Current grant funding | Missing |
| 15. | List of most important publications |
Port, K., Palm, K., Viigimaa M. (2005) Gaily usage and efficiency of remote home monitoring in hypertensive patients over a one-year period. Journal of Teklemedicine and Telecare, 11 Suppl.1, 34-36. Port, K., Palm, K., & Viigimaa, M. (2003). Self-Reported Compliance of Patients Receiving Antihypertensive Treatment: Use of a Telemonitoring Home Care System. Journal of Telemedicine and Telecare, 9, S65-S66. Viigimaa M, Kask A, Tiganik V et al. Cardiovascular risk factors in 55-year-old women and men in Tartu (Estonia) and Stockholm (Sweden). Atherosclerosis Supplements 4 (2):110-110 Sep 2003. Johansson, J., Viigimaa, M., Jensen-Urstad, M., Krakau, I., & Hansson, L. O. (2002). Risk Factors for Coronary Heart Disease in 55-and 35-Year-Old Men and Women in Sweden and Estonia. Journal of Internal Medicine, 252(6), 551-560. Muda P, Ristimäe T, Viigimaa M. Arterial hypertension among middle-aged Estonians - Prevalence and risk factors. Journal of Hypertension 20: P345 Suppl. 4 jun 2002 Allikmets K, Starkopf A, Svensson S et al. Ambulatory blood pressure monitoring in a population of an Estonian island: initial results from the SELECT project. European Heart Journal 22: 10-103. Suppl. S Sep 2001 Unden, A. L., Elofsson, S., Viigimaa, M., Johansson, J., & Knox, S. (2001). A Psychosocial Comparison of 35- and 55-Year-Old Men and Women in Sweden and Estonia: the Swestonia Cardiovascular Risk Factor Study. International Journal of Behavioral Medicine, 8(2), 149-162. Allikmets K., Ristimäe T., Viigimaa M. Electrocardiographic detection of left ventricular hypertrophy in severe essential hypertension: correlations between different models. Journal of Hypertension 18: S28-S28 Suppl. Jun 2000 Svensson S, Allikmets K, Petreson J,.... Viigimaa M... The Swedeshy-Estonian long-term evaluation of cardiovascular risk trends (SELECT) project initial resultsw. Journal of Hypertension 18: S179-S179 Duppl.2 Jun 2000 Viigimaa, M., Allikmets, K., Parik, T., Skards, J., Franken, A., & Hass, G. (2000). Tasosartan and Hydroclorothiazide as Combination Therapy in the Treatment of Severe Essential Hypertension: Comparison With Enalapril. Cardiovascular Drugs and Therapy, 14(4), 447-449. Allikmets, K., Parik, T., & Viigimaa, M. (1999). The Renin-Angiotensin System in Essential Hypertension: Associations With Cardiovascular Risk. Blood Pressure, 8(2), 70-78. Viigimaa M. Baltic Atherosclerosis Journal [2](1999) Clinical Chemistry and Laboratory Medicine, 37 (8),841-841. Viigimaa M, Kask A, Tiganik V et al. Comparision of the lipid profile and eating habits of 35-year and 55-year old inhabitants of the city Tartu (estonia). Atherosckerosis 144: 176-176 Suppl. 1 May 1999 Viigimaa M, Kask A, Tigank V et al. A comparison of blood pressure levels, lipid profiles and smoking habits between 35-year olds in Tartu (Estonia) and Stockholm (Sweden). Hypertension 33 (5): 1320-1320 May 1999 Täpselt sama pealkirjaga ka Hypertension 33 (4): 275 Apr 1999 (?) Viigimaa M, Valkman R. Lipid-lowering and antiaggregatory effacasy of atrovastatin in coronary heart disease patients with combined hyperlipuidamia. Atherosckerosis 144: 24-24 Suppl.1 May 1999 Ojamaa M, Viigimaa M, Slim K et al. Ambulatory blood pressure monitoring in young males with borderline hypertension. Journal of Hypertension 16:L P27117 Suppl. 2 Jun 1998 Parik T, Allikmets K, Zilmer K... Voogomaa M et al, Associations between oxydative stress, Von Willebrand factor and plasminogen activator Inhibitor 1 in essential hypertension. Journal of Hypertension 16: P27041 Suppl.2 Jun 1998 Viigimaa ,M., Välkman, R., Kask, A., Jõudu, T. (1998) Effect of ciprofibrate on platelet aggregation in patients with combined hyperlipidemia. Platelets, 9 (3-4), 265-267. Viigimaa, M., Tsikas, Frölich, J.C. (1996) Platelet aggregation, sensitivity to prostaglandin E1 and tromboxane A2 release in recombinant hirudin- and heparin-anticoagulated blood. Blood Coagulation and Fibrinolysis, 7 (2), 259-261. Viigimaa, M., Joudu, T., Keis, U., Saareoja, Y., Teesalu, R. (1995) Platelet aggregation, tromboxane A2, Prostacycline generation and platelet sensitivity to prostacyclin during the first month after myocardial infarction. Platelets 6 (6), 402-407. Viigimaa M, Saareoja Y. Prospective study on activates protein-C resistance in patients wuth acute myocardial-infarction. Thrombosis and Haemastasis 73 (6): 1374-1374 Jun 1995 Viigimaa M, Ohnogi H, Hattori R et al. Antithrombotic effect and reperfusion by low-molecular-weight heparin in a canine model of coronary-artery thrombosis. Japanese Circulation Journal - English Edistion 57 (6): 553-557. 1993 Lopp M, Kobzar G, Bergamnann M... Viigimaa M,,, Synthesis and anti aggregative activity of novel omega-achiral carba-analogs of prostacyclin. European Journal of Medicinal Chemistry 27 (2): 155-159. Mar 1992 |
last updated: 16.10.2005
[ sulge aken ]